Suspected anaphylaxis during anesthesia induction without identified allergens: a case report

Pub Date : 2023-12-18 DOI:10.1186/s40981-023-00684-y
Sayaka Hirai, Mitsuru Ida, Ai Arima, Masahiko Kawaguchi
{"title":"Suspected anaphylaxis during anesthesia induction without identified allergens: a case report","authors":"Sayaka Hirai, Mitsuru Ida, Ai Arima, Masahiko Kawaguchi","doi":"10.1186/s40981-023-00684-y","DOIUrl":null,"url":null,"abstract":"<p>To the Editor,</p><p>The Japanese Society of Anesthesiologists offers practical guidelines for dealing with perioperative anaphylaxis, emphasizing the importance of anesthesiologists’ involvement in identifying the causative agent to prevent recurrence [1]. However, identifying the causative agents is not always feasible. Herein, we report, with written informed consent, a case where anaphylaxis was suspected during anesthesia induction, yet no allergens were identified.</p><p>A 59-year-old man, 165.5 cm in height and weighing 65.1 kg, presented with congestive heart failure, chronic kidney disease, diabetes, hypertension, and hyperlipidemia, requiring coronary artery bypass grafting for triple-vessel coronary artery disease. The patient had not undergone any surgery previously and had not taken any angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. In the operating room, standard vital signs were closely monitored, and non-invasive blood pressure (NIBP) was recorded at 160/120 mmHg. Anesthesia was induced using remifentanil (rate, 20 mL/h) and remimazolam (12 mg/kg/h). Upon confirming the loss of consciousness, the dosages of remifentanil and remimazolam were reduced to 5 mL/h and 1.0 mg/kg/h, respectively, four minutes after administering rocuronium (60 mg). This was followed by tracheal intubation and arterial catheter insertion. His blood pressure (BP) was 89/67 mm Hg (NIBP) and 47/25 mm Hg (arterial line) immediately before and after tracheal intubation, respectively. Despite fluid resuscitation of 500 mL and multiple boluses of ephedrine (16 mg), phenylephrine (0.3 mg), and norepinephrine (10 µg), he experienced cardiac arrest. During chest compressions, an intravenous bolus of epinephrine (0.1 mg) was administered, resulting in cardiopulmonary resuscitation with an arterial BP of 46/29 mmHg. However, due to persistent severe hypotension, continuous infusions of norepinephrine at 0.1 mcg/kg/min and dobutamine at 5 mcg/kg/min were initiated following additional boluses of epinephrine (0.3 mg). Figure 1 displays the patient’s vital signs during anesthesia. Edema with erythema of the extremities and trunk was observed throughout this sequence, and transesophageal echocardiography revealed no evidence of cardiogenic shock. Consequently, anaphylaxis was suspected, and the patient was transferred to the intensive care unit without proceeding with surgery. Blood samples taken before he left the operating room indicated an elevated serum tryptase level of 17.1 μg/L, exceeding the normal range of 1.2–5.7 μg/L. More than seven weeks after the onset, both basophil activation and skin prick tests using remimazolam and rocuronium yielded negative results. The patient declined surgery and was subsequently followed-up after percutaneous coronary intervention at coronary segments 6, 7, 11, and 14.</p><figure><figcaption><b data-test=\"figure-caption-text\">Fig. 1</b></figcaption><picture><img alt=\"figure 1\" aria-describedby=\"Fig1\" height=\"376\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs40981-023-00684-y/MediaObjects/40981_2023_684_Fig1_HTML.png\" width=\"685\"/></picture><p>The patient’s vital signs during the anesthetic. 0 min, the beginning of anesthetic induction; 3 min, remimazolam and remifentanil were initiated; 4 min, rocuronium was administrated; 8 min, tracheal intubation and securing arterial line; 9 min, phenylephrine 0.1 mg; 10 min, ephedrine 8 mg; 11 min, remimazolam and remifentanil were discontinued; 13 min, phenylephrine 0.2 mg; 14 min, ephedrine 8 mg; 17 min, adrenaline 0.1 mg; 23 min, norepinephrine 0.1 mcg/kg/min, dobutamine 5 mcg/kg/min, and adrenaline 0.3 mg; 28 min, adrenaline 0.3 mg; 30 min, adrenaline 0.3 mg and hydrocortisone 100 mg; 31 min, famotidine 20 mg and hydroxyzine 25 mg. There were no data regarding blood pressure from 6 to 11 minutes after anesthesia induction, as non-invasive blood pressure monitoring was discontinued 6 minutes after anesthesia induction because we expected that it would be replaced by arterial blood pressure monitoring</p><span>Full size image</span><svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></figure><p>Identifying the causative agents is crucial, although it is important to acknowledge the inherent risks [1]. Given the patient's age and the elevated risk of myocardial ischemia, tests were conducted in anticipation of future anesthesia. However, dermatologists opted against an intradermal test due to hypotension preceding skin symptoms during anesthetic induction. Skin tests are considered the gold standard for immunoglobulin E (IgE)-mediated anaphylaxis detection [2]. Considering the patient’s negative results, it is presumed that the anaphylactic reaction was non-IgE-mediated [3]. In this case, serum tryptase levels were measured only once, and the allergens were not identified. This may indicate that the hypotension during anesthetic induction was not due to an allergic reaction; however, the edema with erythema of the extremities and trunk cannot be explained by hypotension caused by excessive anesthetics. Anaphylaxis was suspected during anesthetic induction, and attempts were made to identify the causative agent. Unfortunately, the examination concluded without identifying the suspected drug. Prevention of recurrent anaphylaxis is possible by avoiding the suspect drug. However, continued contraindication of a key agent in general anesthesia, such as rocuronium, is a significant disadvantage for both the anesthesiologist and the patient. Therefore, anesthesiologists should make every effort to identify the causative agent of anaphylaxis.</p><p>Not applicable.</p><dl><dt style=\"min-width:50px;\"><dfn>BP:</dfn></dt><dd>\n<p>Blood pressure</p>\n</dd><dt style=\"min-width:50px;\"><dfn>IgE:</dfn></dt><dd>\n<p>Immunoglobulin E</p>\n</dd><dt style=\"min-width:50px;\"><dfn>NIBP:</dfn></dt><dd>\n<p>Non-invasive blood pressure</p>\n</dd></dl><ol data-track-component=\"outbound reference\"><li data-counter=\"1.\"><p>Takazawa T, Yamaura K, Hara T, Yorozu T, Mitsuhata H, Morimatsu H, et al. Practical guidelines for the response to perioperative anaphylaxis. J Anesth. 2021;35:778–93. https://doi.org/10.1007/s00540-021-03005-8.</p><p>Article PubMed Google Scholar </p></li><li data-counter=\"2.\"><p>Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13:100472. https://doi.org/10.1016/j.waojou.2020.100472.</p><p>Article PubMed PubMed Central Google Scholar </p></li><li data-counter=\"3.\"><p>Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol. 2021;147:1123–31. https://doi.org/10.1016/j.jaci.2021.02.012.</p><p>Article PubMed Google Scholar </p></li></ol><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><p>We would like to thank Editage (www.editage.jp) for English language editing.</p><p>The authors received no financial support for publication of this article.</p><h3>Authors and Affiliations</h3><ol><li><p>Department of Anaesthesiology, Nara Medical University, Kashihara, Nara, Japan</p><p>Sayaka Hirai, Mitsuru Ida &amp; Masahiko Kawaguchi</p></li><li><p>Department of Dermatology, Nara Medical University, Kashihara, Nara, Japan</p><p>Ai Arima</p></li></ol><span>Authors</span><ol><li><span>Sayaka Hirai</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Mitsuru Ida</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Ai Arima</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Masahiko Kawaguchi</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Contributions</h3><p>M.I. wrote the paper. All authors read and approved the final manuscript.</p><h3>Corresponding author</h3><p>Correspondence to Mitsuru Ida.</p><h3>Ethics approval and consent to participate</h3>\n<p>Not applicable.</p>\n<h3>Consent for publication</h3>\n<p>Written informed consent was obtained by the patient.</p>\n<h3>Competing interests</h3>\n<p>The authors declare that they have no competing interests.</p><h3>Publisher’s Note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.</p>\n<p>Reprints and Permissions</p><img alt=\"Check for updates. Verify currency and authenticity via CrossMark\" height=\"81\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\" width=\"57\"/><h3>Cite this article</h3><p>Hirai, S., Ida, M., Arima, A. <i>et al.</i> Suspected anaphylaxis during anesthesia induction without identified allergens: a case report. <i>JA Clin Rep</i> <b>9</b>, 89 (2023). https://doi.org/10.1186/s40981-023-00684-y</p><p>Download citation<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><ul data-test=\"publication-history\"><li><p>Received<span>: </span><span><time datetime=\"2023-10-10\">10 October 2023</time></span></p></li><li><p>Revised<span>: </span><span><time datetime=\"2023-11-28\">28 November 2023</time></span></p></li><li><p>Accepted<span>: </span><span><time datetime=\"2023-12-11\">11 December 2023</time></span></p></li><li><p>Published<span>: </span><span><time datetime=\"2023-12-18\">18 December 2023</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s40981-023-00684-y</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\"click\" data-track-action=\"get shareable link\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\"click\" data-track-action=\"select share url\" data-track-label=\"button\"></p><button data-track=\"click\" data-track-action=\"copy share url\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40981-023-00684-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

To the Editor,

The Japanese Society of Anesthesiologists offers practical guidelines for dealing with perioperative anaphylaxis, emphasizing the importance of anesthesiologists’ involvement in identifying the causative agent to prevent recurrence [1]. However, identifying the causative agents is not always feasible. Herein, we report, with written informed consent, a case where anaphylaxis was suspected during anesthesia induction, yet no allergens were identified.

A 59-year-old man, 165.5 cm in height and weighing 65.1 kg, presented with congestive heart failure, chronic kidney disease, diabetes, hypertension, and hyperlipidemia, requiring coronary artery bypass grafting for triple-vessel coronary artery disease. The patient had not undergone any surgery previously and had not taken any angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. In the operating room, standard vital signs were closely monitored, and non-invasive blood pressure (NIBP) was recorded at 160/120 mmHg. Anesthesia was induced using remifentanil (rate, 20 mL/h) and remimazolam (12 mg/kg/h). Upon confirming the loss of consciousness, the dosages of remifentanil and remimazolam were reduced to 5 mL/h and 1.0 mg/kg/h, respectively, four minutes after administering rocuronium (60 mg). This was followed by tracheal intubation and arterial catheter insertion. His blood pressure (BP) was 89/67 mm Hg (NIBP) and 47/25 mm Hg (arterial line) immediately before and after tracheal intubation, respectively. Despite fluid resuscitation of 500 mL and multiple boluses of ephedrine (16 mg), phenylephrine (0.3 mg), and norepinephrine (10 µg), he experienced cardiac arrest. During chest compressions, an intravenous bolus of epinephrine (0.1 mg) was administered, resulting in cardiopulmonary resuscitation with an arterial BP of 46/29 mmHg. However, due to persistent severe hypotension, continuous infusions of norepinephrine at 0.1 mcg/kg/min and dobutamine at 5 mcg/kg/min were initiated following additional boluses of epinephrine (0.3 mg). Figure 1 displays the patient’s vital signs during anesthesia. Edema with erythema of the extremities and trunk was observed throughout this sequence, and transesophageal echocardiography revealed no evidence of cardiogenic shock. Consequently, anaphylaxis was suspected, and the patient was transferred to the intensive care unit without proceeding with surgery. Blood samples taken before he left the operating room indicated an elevated serum tryptase level of 17.1 μg/L, exceeding the normal range of 1.2–5.7 μg/L. More than seven weeks after the onset, both basophil activation and skin prick tests using remimazolam and rocuronium yielded negative results. The patient declined surgery and was subsequently followed-up after percutaneous coronary intervention at coronary segments 6, 7, 11, and 14.

Fig. 1
Abstract Image

The patient’s vital signs during the anesthetic. 0 min, the beginning of anesthetic induction; 3 min, remimazolam and remifentanil were initiated; 4 min, rocuronium was administrated; 8 min, tracheal intubation and securing arterial line; 9 min, phenylephrine 0.1 mg; 10 min, ephedrine 8 mg; 11 min, remimazolam and remifentanil were discontinued; 13 min, phenylephrine 0.2 mg; 14 min, ephedrine 8 mg; 17 min, adrenaline 0.1 mg; 23 min, norepinephrine 0.1 mcg/kg/min, dobutamine 5 mcg/kg/min, and adrenaline 0.3 mg; 28 min, adrenaline 0.3 mg; 30 min, adrenaline 0.3 mg and hydrocortisone 100 mg; 31 min, famotidine 20 mg and hydroxyzine 25 mg. There were no data regarding blood pressure from 6 to 11 minutes after anesthesia induction, as non-invasive blood pressure monitoring was discontinued 6 minutes after anesthesia induction because we expected that it would be replaced by arterial blood pressure monitoring

Full size image

Identifying the causative agents is crucial, although it is important to acknowledge the inherent risks [1]. Given the patient's age and the elevated risk of myocardial ischemia, tests were conducted in anticipation of future anesthesia. However, dermatologists opted against an intradermal test due to hypotension preceding skin symptoms during anesthetic induction. Skin tests are considered the gold standard for immunoglobulin E (IgE)-mediated anaphylaxis detection [2]. Considering the patient’s negative results, it is presumed that the anaphylactic reaction was non-IgE-mediated [3]. In this case, serum tryptase levels were measured only once, and the allergens were not identified. This may indicate that the hypotension during anesthetic induction was not due to an allergic reaction; however, the edema with erythema of the extremities and trunk cannot be explained by hypotension caused by excessive anesthetics. Anaphylaxis was suspected during anesthetic induction, and attempts were made to identify the causative agent. Unfortunately, the examination concluded without identifying the suspected drug. Prevention of recurrent anaphylaxis is possible by avoiding the suspect drug. However, continued contraindication of a key agent in general anesthesia, such as rocuronium, is a significant disadvantage for both the anesthesiologist and the patient. Therefore, anesthesiologists should make every effort to identify the causative agent of anaphylaxis.

Not applicable.

BP:

Blood pressure

IgE:

Immunoglobulin E

NIBP:

Non-invasive blood pressure

  1. Takazawa T, Yamaura K, Hara T, Yorozu T, Mitsuhata H, Morimatsu H, et al. Practical guidelines for the response to perioperative anaphylaxis. J Anesth. 2021;35:778–93. https://doi.org/10.1007/s00540-021-03005-8.

    Article PubMed Google Scholar

  2. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13:100472. https://doi.org/10.1016/j.waojou.2020.100472.

    Article PubMed PubMed Central Google Scholar

  3. Cianferoni A. Non-IgE-mediated anaphylaxis. J Allergy Clin Immunol. 2021;147:1123–31. https://doi.org/10.1016/j.jaci.2021.02.012.

    Article PubMed Google Scholar

Download references

We would like to thank Editage (www.editage.jp) for English language editing.

The authors received no financial support for publication of this article.

Authors and Affiliations

  1. Department of Anaesthesiology, Nara Medical University, Kashihara, Nara, Japan

    Sayaka Hirai, Mitsuru Ida & Masahiko Kawaguchi

  2. Department of Dermatology, Nara Medical University, Kashihara, Nara, Japan

    Ai Arima

Authors
  1. Sayaka HiraiView author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuru IdaView author publications

    You can also search for this author in PubMed Google Scholar

  3. Ai ArimaView author publications

    You can also search for this author in PubMed Google Scholar

  4. Masahiko KawaguchiView author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.I. wrote the paper. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mitsuru Ida.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent was obtained by the patient.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

Abstract Image

Cite this article

Hirai, S., Ida, M., Arima, A. et al. Suspected anaphylaxis during anesthesia induction without identified allergens: a case report. JA Clin Rep 9, 89 (2023). https://doi.org/10.1186/s40981-023-00684-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40981-023-00684-y

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
麻醉诱导过程中疑似过敏性休克,但未发现过敏原:病例报告
致编辑:日本麻醉医师学会提供了处理围术期过敏性休克的实用指南,强调了麻醉医师参与确定致病因子以防止复发的重要性[1]。然而,确定致病因子并不总是可行的。一位身高 165.5 厘米、体重 65.1 千克的 59 岁男性患者患有充血性心力衰竭、慢性肾病、糖尿病、高血压和高脂血症,因三支冠状动脉病变需要进行冠状动脉搭桥术。患者此前未接受过任何手术,也未服用过任何血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂。在手术室,医生密切监测标准生命体征,无创血压(NIBP)记录为 160/120 mmHg。使用瑞芬太尼(速率,20 毫升/小时)和瑞美唑仑(12 毫克/千克/小时)进行麻醉诱导。在确认意识丧失后,瑞芬太尼和瑞马唑仑的剂量分别降至 5 毫升/小时和 1.0 毫克/千克/小时,四分钟后注射罗库溴铵(60 毫克)。随后进行了气管插管和动脉导管插入。气管插管前后的血压(BP)分别为 89/67 mm Hg(无创伤血压)和 47/25 mm Hg(动脉导管)。尽管进行了 500 毫升的液体复苏,并多次注射麻黄碱(16 毫克)、苯肾上腺素(0.3 毫克)和去甲肾上腺素(10 微克),他还是出现了心跳骤停。在胸外按压过程中,静脉注射了肾上腺素(0.1 毫克),心肺复苏成功,动脉血压为 46/29 毫米汞柱。然而,由于持续严重低血压,在追加注射肾上腺素(0.3 毫克)后,又开始持续输注去甲肾上腺素(0.1 微克/千克/分钟)和多巴酚丁胺(5 微克/千克/分钟)。图 1 显示了麻醉期间患者的生命体征。在整个过程中观察到四肢和躯干水肿并伴有红斑,经食道超声心动图检查没有发现心源性休克的迹象。因此,医生怀疑是过敏性休克,于是将病人转到重症监护室,没有继续手术。在他离开手术室前采集的血样显示,血清胰蛋白酶水平升高至 17.1 μg/L,超过了 1.2-5.7 μg/L的正常范围。发病七周多后,嗜碱性粒细胞激活试验和使用雷马唑仑和罗库溴铵进行的皮肤点刺试验结果均为阴性。患者拒绝手术,随后在冠状动脉第 6、7、11 和 14 节经皮冠状动脉介入治疗后接受了随访。0 分钟,麻醉诱导开始;3 分钟,开始使用瑞马唑仑和瑞芬太尼;4 分钟,使用罗库溴铵;8 分钟,气管插管并固定动脉管路;9 分钟,使用苯肾上腺素 0.1 毫克;10 分钟,使用麻黄碱 8 毫克;11 分钟,停止使用瑞马唑仑和瑞芬太尼;13 分钟,使用苯肾上腺素 0.2 毫克;14 分钟,麻黄碱 8 毫克;17 分钟,肾上腺素 0.1 毫克;23 分钟,去甲肾上腺素 0.1 微克/千克/分钟、多巴酚丁胺 5 微克/千克/分钟和肾上腺素 0.3 毫克;28 分钟,肾上腺素 0.3 毫克;30 分钟,肾上腺素 0.3 毫克和氢化可的松 100 毫克;31 分钟,法莫替丁 20 毫克和羟嗪 25 毫克。没有关于麻醉诱导后 6 至 11 分钟血压的数据,因为在麻醉诱导后 6 分钟停止了无创血压监测,因为我们预计动脉血压监测将取代无创血压监测。考虑到患者的年龄和心肌缺血风险的升高,我们进行了预期未来麻醉的测试。然而,由于在麻醉诱导过程中出现皮肤症状之前会出现低血压,皮肤科医生选择不进行皮内测试。皮试被认为是检测免疫球蛋白 E(IgE)介导的过敏性休克的黄金标准[2]。考虑到患者的检测结果为阴性,因此推测过敏性反应并非由免疫球蛋白 E(IgE)介导[3]。在该病例中,只检测了一次血清色氨酸酶水平,但并未确定过敏原。这可能表明,麻醉诱导期间的低血压并非过敏反应所致;但是,四肢和躯干的水肿和红斑无法用过多麻醉剂导致的低血压来解释。在麻醉诱导过程中怀疑发生了过敏性休克,并试图找出致病因子。遗憾的是,检查结束时并未确定可疑药物。避免使用可疑药物可预防过敏性休克再次发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1